<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092841</url>
  </required_header>
  <id_info>
    <org_study_id>TSL-CM-PXT3003-Ⅲ</org_study_id>
    <nct_id>NCT05092841</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceutical Group Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled and multicenter 3 phase trial&#xD;
      evaluating the therapeutic effect and safety of CMT1A by PXT3003. This double-blind study&#xD;
      will assess in parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients&#xD;
      treated for 15 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, randomized, double-blind, placebo-controlled, Phase III clinical study is&#xD;
      designed to evaluate PXT3003 versus placebo in subjects with genetically confirmed CMT1A of&#xD;
      mild-to-moderate severity (CMTNS-V2 score &gt;2 and ≤18) aged 16 to 65 years.&#xD;
&#xD;
      Genetically confirmed CMT1A subjects will be screened and randomized in a 1:1 ratio to&#xD;
      receive either oral PXT3003 daily or matching placebo for 15 months. A total of approximately&#xD;
      176 subjects will be enrolled.&#xD;
&#xD;
      Visits will take place at Screening (up to -30 days), Baseline , and Months 3, 6, 9, 12, and&#xD;
      15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Neuropathy Limitation Scale (ONLS) score</measure>
    <time_frame>15 months</time_frame>
    <description>The primary efficacy endpoint will be the main effect of the studied treatment on the improvement of disability measured by the Overall Neuropathy Limitation Scale (ONLS) score, summarized at 15 months defined by: the change of the ONLS from baseline to the 15 months.ONLS is a disability scale that was derived and improved from the Overall Disability Sum Score to measure limitations in the everyday activities of the upper limbs (rated in 5 points) and the lower limbs (rated on 7 points) . The total score goes from 0 ( no disability) to 12 (maximum disability).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment responders rate of PXT3003;</measure>
    <time_frame>15 months</time_frame>
    <description>Responders Rate to PXT3003 therapy defined as a patients improving on ONLS at end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The sub-item of Arm and leg scores in Overall Neuropathy Limitation Scale (ONLS)</measure>
    <time_frame>15 months</time_frame>
    <description>ONLS is a disability scale that was derived and improved from the Overall Disability Sum Score to measure limitations in the everyday activities of the upper limbs (rated in 5 points) and the lower limbs (rated on 7 points) . The total score goes from 0 ( no disability) to 12 (maximum disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and sub-item score of Charcot-Marie-Tooth neuropathy score second version (CMTNS-V2);</measure>
    <time_frame>15 months</time_frame>
    <description>CMTNS is a specific scale designed to assess severity of impairment in CMT disease .Although not completely validated, it provides a single and reliable measure of CMT severity. It is a 36-point scale based on 9 items: 5 of them quantify impairment (sensory symptoms, pin sensibility, vibration, arm and leg strength).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-Meter Walk Test (10MWT);</measure>
    <time_frame>15 months</time_frame>
    <description>Record the time for walk 10 meters . 10m WT is simple to administer, standardized, reliable and valid evaluation of functional exercise capacity and gait that has been proven reliable in neurologic disorders and in CMT patients. Results recorded are the time to walk 10 meters and the number of steps performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nine-hole peg test (9HPT) for non-dominant hand ;</measure>
    <time_frame>15 months</time_frame>
    <description>The 9-HPT is a simple timed test of fine motor coordination of extremities in the upper limbs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantified Muscular Testing (QMT) (grip strength and bilateral foot dorsiflexion dynamometry) ;</measure>
    <time_frame>15 months</time_frame>
    <description>QMT is used to evaluate motor strength in CMT1A. The following muscles will be evaluated: hand grip (right and left).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological parameters Sensory responses measured at ulnar and radial nerves on the non-dominant side:</measure>
    <time_frame>15 months</time_frame>
    <description>The assessment parameters including: Distal motor latency (DML) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological parameters motor responses measured at ulnar and radial nerves on the non-dominant side</measure>
    <time_frame>15 months</time_frame>
    <description>The assessment parameters including: Nerve conduction velocity (NCV) .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Charcot-Marie-Tooth Type 1A</condition>
  <arm_group>
    <arm_group_label>PXT3003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liquid oral solution, 10 mL twice a day, morning and evening with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT3003 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Liquid oral solution, 10 mL twice a day, morning and evening with food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003</intervention_name>
    <description>Patients will be administered PXT3003 twice daily (bid) at 10mL.</description>
    <arm_group_label>PXT3003</arm_group_label>
    <other_name>(RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003 placebo</intervention_name>
    <description>Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.</description>
    <arm_group_label>PXT3003 Placebo</arm_group_label>
    <other_name>liquid oral solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 16 to 65 years (included boundary value), of either sex;&#xD;
&#xD;
          2. Patients with CMT1A (PMP22 duplication on chromosome 17p11.2) confirmed by gene&#xD;
             diagnosis; 3.2 &lt; CMTNS-v2 score ≤ 18;&#xD;
&#xD;
        4.Patients are dorsalis pedis flexor weakness at least (clinical evaluation); 5.Ulnar nerve&#xD;
        motor nerve conductance velocity &gt; 15 m/s; 6.Subjects participate in clinical trials and&#xD;
        sign informed consent voluntarily , and they have the ability to understand as will as&#xD;
        abide by research procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Being allergic to RS-baclofen, naltrexone HCL, D-sorbitol or any component in pxt3003&#xD;
             excipients or having other serious prior allergic reaction;&#xD;
&#xD;
          2. Existence contraindications of baclofen, naltrexone or sorbitol, such as porphyria;&#xD;
&#xD;
          3. Any other associated cause of peripheral neuropathy such as diabetes mellitus&#xD;
             (including diabetes history and glycosylated hemoglobin &gt;6.5%)&#xD;
&#xD;
          4. Subjects with other neurological diseases affecting the evaluation of study treatment;&#xD;
&#xD;
          5. Patients with the score of ONLS score is 0;&#xD;
&#xD;
          6. A history of unstable medical diseases with clinically significant unstable medical&#xD;
             diseases (unstable angina pectoris, tumor, blood disease, hepatitis or liver failure,&#xD;
             renal failure, etc.) that may cause harm to the subjects participating in this study&#xD;
             in the past 1 year;&#xD;
&#xD;
          7. Limb surgery had implemented within the first six months of randomization or will be&#xD;
             planned before the completion of the clinical trial;&#xD;
&#xD;
          8. Hepatic or renal dysfunction:&#xD;
&#xD;
               1. TBIL&gt;1.5×ULN,ALT&gt;3×ULN,AST&gt;3×ULN;&#xD;
&#xD;
               2. Cr&gt;1.5×ULN;&#xD;
&#xD;
          9. Syphilis antibody and HIV antibody positive subjects;&#xD;
&#xD;
         10. Subjects with tumors indicated by chest radiograph or B-ultrasound;&#xD;
&#xD;
         11. Subjects with alcohol dependence in recent 3 months;&#xD;
&#xD;
         12. Females that are of childbearing potential, pregnant, or are breast-feeding;Subjects&#xD;
             who are unable to use appropriate contraceptives during the trial;&#xD;
&#xD;
         13. Subjects with concomitant treatment 4 weeks before enrollment, including but not&#xD;
             limited to baclofen, naltrexone, sorbitol, opioids, vitamin C, levothyroxine and&#xD;
             potentially neurotoxic drugs (such as amiodarone and chloroquine);&#xD;
&#xD;
         14. Subjects unable to complete the follow-up of study;&#xD;
&#xD;
         15. Participated in another clinical trial and used the test drug within the last 30 days;&#xD;
&#xD;
         16. Different subjects from the same family and living in the same residence can only&#xD;
             include one subject, so as to avoid treatment confusion, affect blind treatment and&#xD;
             affect the interpretation of the research results;&#xD;
&#xD;
         17. Investigators affirm the compliance in a certain subject is poor or there are some&#xD;
             other factors that are not suitable to participate in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Liu</last_name>
    <role>Study Director</role>
    <affiliation>Tasly Group,Co.Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Liu</last_name>
    <phone>022-86343626</phone>
    <email>liurui2@tasly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dongsheng Fan</last_name>
      <phone>13701023871</phone>
      <email>dsfan@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuwei Da</last_name>
      <phone>18811182130</phone>
      <email>dayuwei100@hormail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Sun</last_name>
      <phone>13596116866</phone>
      <email>sjnksunxin@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruxu Zhang</last_name>
      <phone>18975172668</phone>
      <email>zhangruxu@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ning Wang</last_name>
      <phone>13805015340</phone>
      <email>26354378@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haishan Jiang</last_name>
      <phone>18665604153</phone>
      <email>jianghs@smu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital，Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoli Yao</last_name>
      <phone>18902233583</phone>
      <email>yeyaoxiaoli@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shan Wu</last_name>
      <phone>13312231575</phone>
      <email>wuwushan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiying Wu</last_name>
      <phone>13646715353</phone>
      <email>zhiyingwu@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guozhong Li</last_name>
      <phone>13804606966</phone>
      <email>hydlgz1962@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kai Wang</last_name>
      <phone>13805512494</phone>
      <email>wangkai1964@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Runxiu Zhu</last_name>
      <phone>13337101828</phone>
      <email>zhurunxiu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiming Liu</last_name>
      <phone>18560085383</phone>
      <email>Liuym@sdu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Longjiang Tu</last_name>
      <phone>13755697779</phone>
      <email>tujianglong85@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yun Xu</last_name>
      <phone>13914764479</phone>
      <email>xuyun20042001@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baoyu Yuan</last_name>
      <phone>15850557266</phone>
      <email>Yuanby1978@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University（Qingdao）</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuanzhu Yan</last_name>
      <phone>18560089977</phone>
      <email>czyan@sdu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Liu</last_name>
      <phone>15221303819</phone>
      <email>jly0520@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiyi He</last_name>
      <phone>13504903529</phone>
      <email>hezhiyi0301@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaling Liu</last_name>
      <phone>15803210553</phone>
      <email>lyldoctor@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qi Fang</last_name>
      <phone>13606213892</phone>
      <email>Larryfisher6@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University（Hubei General Hospital）</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zuneng Lu</last_name>
      <phone>13995672166</phone>
      <email>lzn196480@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jingxia Dang</last_name>
      <phone>13379262486</phone>
      <email>Jxdang2000@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingming Ma</last_name>
      <phone>13526436608</phone>
      <email>Macklon12@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuming Xu</last_name>
      <phone>13903711125</phone>
      <email>13903711125@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Baclofen</mesh_term>
    <mesh_term>Sorbitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

